《大行報告》高盛下調聯易融科技(09959.HK)目標價至18.5元 評級「買入」
高盛發表研究報告指,聯易融科技(09959.HK)第三季交易量按年增48%至785億元人民幣(較高盛預測高4%),主要來自供應鏈金融科技解決方案的增長,而旗下AMS雲和ABS雲亦較預期高10%。
該行調低2021至23年收入預期分別1%、2%及4%,以反映第三季ABS營運表現強勁主要來自非標準化業務爲主,而其他業務表現遜預期、長遠整體業務較波動,相信公司將持續多元化收入來源;經調整利潤分別調低5%、9%及9%,以反映更多新產品投資,目標價由21.6元降至18.5元,評級「買入」。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.